NCIMB Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NCIMB Ltd. - overview
Established
1982
Location
Aberdeen, Scotland, UK
Primary Industry
Biotechnology
About
NCIMB Ltd. , based in the UK, provides specialized microbiology services, including the identification, characterization, and storage of microorganisms vital for research and industry applications. NCIMB Ltd. offers microbiology services and operates from its headquarters in Aberdeen, UK, since its establishment in 1982.
The company has engaged in one deal, with the most recent transaction taking place on April 29, 2025. CEO Carol P. leads the team, enhancing the company's strategic direction and operational focus. NCIMB specializes in microbiology services encompassing the supply, identification, characterization, quantification, and storage of microorganisms.
They maintain the UK’s largest public repository of bacterial reference strains and provide laboratory services such as microbial identification, whole genome sequencing, chemical analysis, and ecotoxicity testing. Their clientele includes sectors like pharmaceuticals, agriculture, food and drink, oil and gas, and environmental services, supporting advancements in microbial product development globally. In 2023, NCIMB reported a revenue of GBP 2,552,739. 10 and an EBITDA loss of GBP 278,805.
50. The company generates revenue through a B2B model, involving contract research projects and sales of specialized microbiology products tailored to client needs. In April 2025, NCIMB secured GBP 1. 7 million in debt financing from The FSE Group, Maven Equity Partners, and Scottish National Investment Bank to bolster business development and marketing capabilities.
This funding will support the advancement of microbiology and strain licensing services, with plans to enhance product offerings and expand into new markets by the end of 2025.
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.ncimb.com
Total Amount Raised
Subscriber access only
NCIMB Ltd. - timeline of key events
NCIMB Ltd. - financials
| Fiscal Year Ended | Jul 31, 2012 | Jul 31, 2013 | Jul 31, 2014 | Jul 31, 2015 | Jul 31, 2016 | Jul 31, 2017 | Jul 31, 2018 | Jul 31, 2019 | Jul 31, 2020 | Jul 31, 2021 | Jul 31, 2022 | Jul 31, 2023 | Jul 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,322,603 | 1,356,819 | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | 2.6% | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | 187,551 | 205,357 | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income (USD) | 121,097 | 139,193 | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | 9.2% | 10.3% | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | 14.2% | 15.1% | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | 115,586 | 126,581 | - | - | - | - | - | - | - | - | - | - | - |
| % Net Margin | 8.7% | 9.3% | - | - | - | - | - | - | - | - | - | - | - |
NCIMB Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | NCIMB Ltd. | - |
Displaying 1 - 1 of 1
NCIMB Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.